{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:03:45Z","timestamp":1794603825504,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Liver fibrosis is a chronic fibrosing hepatic disorder following recurrent injury, characterized by the excessive accumulation of extracellular matrix. Early detection has a great clinical impact because 80\u201390% of hepatocellular carcinomas are known to develop in fibrotic or cirrhotic (end-stage fibrotic) livers. PET imaging with FAP ligands exhibited highly promising results in recent years to visualize fibrosis in various organs due to the crucial role of activated fibroblasts in fibrosing processes. However, still little is known about the efficacy of FAP imaging in liver fibrosis. Thus, we sought to investigate the potential of FAPI-PET in a cohort of oncological and non-oncological patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>199 patients who underwent FAPI-PET\/CT at the University Hospital of Heidelberg between July 2017 and July 2020 were retrospectively analyzed. The tracer uptake of the liver was analyzed and correlated with radiological and clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed a weak but significant negative correlation between the hepatic FAPI uptake and CT density (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212 0.273,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001***). A positive correlation was observed between hepatic FAPI uptake and the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.183,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009**), an established surrogate for liver fibrosis. The liver SUV (standardized uptake value) mean and SUVmax of FAPI showed significant differences between groups of patients with low (&lt;\u20090.5), middle (0.5\u20131.0) and higher (&gt;\u20091.0) levels of APRI (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001***).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These preliminary observational results suggest that FAPI-PET may be a viable non-invasive method to asses liver fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-025-02027-6","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T23:03:40Z","timestamp":1741215820000},"page":"631-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of [68Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-0559","authenticated-orcid":false,"given":"Yuriko","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Novruzov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mavriopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven H.","family":"Loosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"R\u00f6hrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"4","key":"2027_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875.","journal-title":"Cells"},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749\u201361.","journal-title":"Lancet"},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12889-024-17948-6","volume":"24","author":"XN Wu","year":"2024","unstructured":"Wu XN, Xue F, Zhang N, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health. 2024;24:363.","journal-title":"BMC Public Health"},{"key":"2027_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118\u201327.","journal-title":"N Engl J Med"},{"issue":"121","key":"2027_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","volume":"1","author":"T Higashi","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;1(121):27\u201342.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2027_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cells9010024","volume":"9","author":"O Khomich","year":"2019","unstructured":"Khomich O, Ivanov AV, Bartosch B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis. Cells. 2019;9(1):24.","journal-title":"Cells"},{"issue":"1","key":"2027_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2741\/4706","volume":"24","author":"AJ Lay","year":"2019","unstructured":"Lay AJ, Zhang HE, McCaughan GW, Gorrell MD. Fibroblast activation protein in liver fibrosis. Front Biosci (Landmark Ed). 2019;24(1):1\u201317.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"13","key":"2027_CR8","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.2741\/2918","volume":"1","author":"XM Wang","year":"2008","unstructured":"Wang XM, Yao TW, Nadvi NA, et al. Fibroblast activation protein and chronic liver disease. Front Biosci. 2008;1(13):3168\u201380.","journal-title":"Front Biosci"},{"key":"2027_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, J\u00e4ger D, Flechsig P, Altmann A, et al. 68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP targeting agents in patients with various cancers. J Nucl Med. 2019;60:386\u201392.","journal-title":"J Nucl Med"},{"key":"2027_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05307-1","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05307-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2027_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, R\u00f6hrich M, Winter H, et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med"},{"issue":"5","key":"2027_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11604-024-01528-0","volume":"42","author":"W Rao","year":"2024","unstructured":"Rao W, Fang XH, Zhao Y, et al. Clinical value of [(18)F]AlF-NOTA-FAPI-04 PET\/CT for assessing early-stage liver fibrosis in adult liver transplantation recipients compared with chronic HBV patients. Jpn J Radiol. 2024;42(5):536\u201345.","journal-title":"Jpn J Radiol"},{"issue":"2","key":"2027_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4274\/mirt.galenos.2022.80774","volume":"32","author":"G Tatar","year":"2023","unstructured":"Tatar G, Beyhan E, Erol Fenercio\u011flu \u00d6, et al. (68)Ga-FAPI-04 PET\/CT findings in patients with liver cirrhosis. Mol Imaging Radionucl Ther. 2023;32(2):146\u20139. https:\/\/doi.org\/10.4274\/mirt.galenos.2022.80774.","journal-title":"Mol Imaging Radionucl Ther"},{"key":"2027_CR14","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, Distler JHW, Treutlein C, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2021;3:e185\u201394.","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"2027_CR15","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1007\/s00259-021-05660-1","volume":"49","author":"P Conen","year":"2022","unstructured":"Conen P, Pennetta F, Dendl K, Hertel F, Vogg A, Haberkorn U, Giesel FL, Mottaghy FM. [68Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease. Eur J Nucl Med Mol Imaging. 2022;49(10):3365\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2027_CR16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2): e220749.","journal-title":"Radiology"},{"issue":"12","key":"2027_CR17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.121.263736","volume":"63","author":"A Pirasteh","year":"2022","unstructured":"Pirasteh A, Periyasamy S, Meudt JJ, et al. Staging liver fibrosis by fibroblast activation protein inhibitor PET in a human-sized swine model. J Nucl Med. 2022;63(12):1956\u201361.","journal-title":"J Nucl Med"},{"key":"2027_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06773-z","author":"Y Song","year":"2024","unstructured":"Song Y, Qin C, Chen Y, et al. Non-invasive visualization of liver fibrosis with [(68)Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06773-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2027_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","volume":"65","author":"G Marrone","year":"2016","unstructured":"Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol. 2016;65:608\u201317.","journal-title":"J Hepatol"},{"issue":"45","key":"2027_CR20","doi-asserted-by":"publisher","first-page":"16820","DOI":"10.3748\/wjg.v20.i45.16820","volume":"20","author":"S Sharma","year":"2014","unstructured":"Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol. 2014;20(45):16820\u201330.","journal-title":"World J Gastroenterol"},{"key":"2027_CR21","doi-asserted-by":"publisher","first-page":"109575","DOI":"10.1016\/j.ejrad.2021.109575","volume":"136","author":"K Morita","year":"2021","unstructured":"Morita K, Nishie A, Ushijima Y, et al. Noninvasive assessment of liver fibrosis by dual-layer spectral detector CT. Eur J Radiol. 2021;136:109575.","journal-title":"Eur J Radiol"},{"issue":"8","key":"2027_CR22","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1007\/s00330-021-07706-2","volume":"31","author":"Y Nagayama","year":"2021","unstructured":"Nagayama Y, Kato Y, Inoue T, et al. Liver fibrosis assessment with multiphasic dual-energy CT: diagnostic performance of iodine uptake parameters. Eur Radiol. 2021;31(8):5779\u201390.","journal-title":"Eur Radiol"},{"issue":"1","key":"2027_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101761","volume":"46","author":"J Boursier","year":"2022","unstructured":"Boursier J, Decraecker M, Bourli\u00e8re M, et al. Quality criteria for the measurement of liver stiffness. Clin Res Hepatol Gastroenterol. 2022;46(1): 101761.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10","key":"2027_CR24","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-2036.2010.04276.x","volume":"31","author":"GL Wong","year":"2010","unstructured":"Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31(10):1095\u2013103.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2027_CR25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"2","key":"2027_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"key":"2027_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver. Asociaci\u00f3n Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237\u201364.","journal-title":"J Hepatol"},{"issue":"23","key":"2027_CR28","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3748\/wjg.v12.i23.368220","volume":"12","author":"G Sebastiani","year":"2006","unstructured":"Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12(23):3682\u201394. https:\/\/doi.org\/10.3748\/wjg.v12.i23.368220.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2027_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cld.2008.07.010","volume":"12","author":"I Guha","year":"2008","unstructured":"Guha I, Rosenberg W. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis. 2008;12(4):883\u2013900.","journal-title":"Clin Liver Dis"},{"issue":"36","key":"2027_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030488","volume":"101","author":"FP Sapmaz","year":"2022","unstructured":"Sapmaz FP, B\u00fcy\u00fckturan G, Sakin YS, et al. How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients? Medicine (Baltimore). 2022;101(36): e30488.","journal-title":"Medicine (Baltimore)"},{"key":"2027_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-230X-12-14","volume":"12","author":"W Jin","year":"2012","unstructured":"Jin W, Lin Z, Xin Y, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012;12:14.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"2027_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199760","volume":"13","author":"YH Yen","year":"2018","unstructured":"Yen YH, Kuo FY, Kee KM, et al. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS ONE. 2018;13(6): e0199760.","journal-title":"PLoS ONE"},{"key":"2027_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","volume":"61","author":"G Xiao","year":"2015","unstructured":"Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292\u2013302.","journal-title":"Hepatology"},{"key":"2027_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1665-2681(19)31410-3","volume":"11","author":"TG Amorim","year":"2012","unstructured":"Amorim TG, Staub GI, Lazzarotto C, et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol. 2012;11:855\u201361.","journal-title":"Ann Hepatol"},{"issue":"11","key":"2027_CR35","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","volume":"20","author":"I Graupera","year":"2022","unstructured":"Graupera I, Thiele M, Serra-Burriel M, et al. Investigators of the liverscreen consortium. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20(11):2567\u201376.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02027-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:13:07Z","timestamp":1747800787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02027-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02027-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5341784\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FLG has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and shares a consultancy group for iTheranostics. FLG is also an advisor at ABX, Telix, Alpha Fusion and SOFIE Biosciences. C.K. Royalties from SOFIE Biosciences and iTheranostics; patents for FAP inhibitors; participates on advisory board on neuroendocrine tumors for Advanced Accelerator Applications Germany, a Novartis company; stock or stock options in FAPi-Holding. U.H. Royalties from iTheranostics and SOFIE Biosciences; patent for FAPI tracers licensed to SOFIE Biosciences. The other authors declare no conflict of interest regarding this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were approved by regional ethics committee board (approval S358\/2022) and carried out in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}